Three major smoking cessation therapies pose no serious heart risks

Three major types of smoking cessation therapies don't increase the risk of heart attack, stroke or heart-related death, according to research published in the American Heart Association journal Circulation.

In recent years, there has been concern that some products may have serious cardiovascular risks. But in the largest analysis of side effects (63 clinical trials and 30,508 people), serious heart events didn't increase with nicotine replacement gums and patches or the nicotine addiction treatment varenicline (Chantix), and the antidepressant bupropion (Wellbutrin) protected against serious heart events.

"Undoubtedly, the benefits of quitting smoking outweigh any potential risks from smoking cessation therapies," said Edward J. Mills, Ph.D., M.Sc., study co-author and associate professor of medicine at Stanford University and Canada Research Chair at the University of Ottawa.

Smoking cessation is associated with improved cardiovascular health, increased life expectancy, improved quality of life and reduced healthcare costs for smoking-associated conditions.

Nicotine replacement therapy via patch or gum increased the risk of minor heart symptoms such as a rapid or irregular heartbeat, researchers said.

"These more minor risks are well known to clinicians and usually pass with time," Mills said. "They occur most often when people are taking and smoking at the same time, which is a bad idea."

Previously, the researchers found that combination therapy—wearing a patch and using when there is the urge to smoke—may be more effective but lead to more side effects than the gum or patch alone.

Most patients in the analysis were relatively healthy, so the results may not be true for everyone.

"It's possible that the risk factors might be different in people with multiple diseases," Mills said. "Patients should discuss with their healthcare provider any potential risk factors that they may have developed from their smoking history. For patients who have chronic lung disease or other associated cardiovascular risks, clinicians should determine which smoking cessation aid to use by their risk profiles."

Related Stories

Quitting smoking: Licensed medications are effective

date May 30, 2013

Nicotine replacement therapy and other licensed drugs can help people quit smoking, according to a new systematic review published in The Cochrane Library. The study, which is an overview of previous Cochrane reviews, suppor ...

Short-term smoking cessation reverses endothelial damage

date Sep 01, 2013

Eight weeks of smoking cessation reverses the endothelial damage caused by smoking, according to research presented at the ESC Congress today by Dr. Yasuaki Dohi from Japan. Serotonin remained elevated, suggesting eight weeks ...

Recommended for you

Cognitive impairment predicts worse outcome in heart failure

date May 24, 2015

Cognitive impairment predicts worse outcome in elderly heart failure patients, reveals research presented today at Heart Failure 2015 by Hiroshi Saito, a physiotherapist at Kameda Medical Centre in Kamogawa, Japan. Patients ...

1950s drug is future heart treatment

date May 22, 2015

Oxford University researchers have found a promising future treatment for heart disease, going back to a drug first developed in 1950.

Time is muscle in acute heart failure

date May 21, 2015

Urgent diagnosis and treatment in acute heart failure has been emphasised for the first time in joint recommendations published today in European Heart Journal.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.